.Competing passions.R.S., M.S., H.G. as well as A.A.R. are actually organizers of the 1M1M project. H.G. as well as A.A.R. are actually panel of directors participants and R.S., M.S. and also A.A.R. are participants of the clinical advisory committee of N1C. A.A.R. discloses work by LUMC, which possesses patents on exon-skipping modern technology, several of which has actually been accredited to BioMarin and ultimately sublicensed to Sarepta. As co-inventor of some of these patents, A.A.R. was qualified to a reveal of nobilities. A.A.R. further reveals serving as impromptu specialist for PTC Therapeutics, Sarepta Therapeutics, Regenxbio, Dyne Therapeutics, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and Astra Zeneca. Over the last 5 years, A.A.R. likewise executed ad hoc consulting for Alpha Anomeric. A.A.R. likewise states membership of the clinical boards of advisers of Eisai, Hybridize Therapeutics, Silence Rehabs, Sarepta Therapies, Sapreme and Mitorx. Previously 5 years, A.A.R. was actually likewise a clinical board of advisers member for ProQR. Commission for A.A.R. u00e2 s consulting and also recommending tasks is paid out to LUMC. Over the last 5 years, LUMC likewise acquired sound speaker honoraria coming from PTC Rehabs, Alnylam Netherlands, Italfarmaco as well as Pfizer and also funding for agreement investigation coming from Sapreme, Eisai, Galapagos, Synaffix as well as Alpha Anomeric. Venture financing is received from Sarepta Therapeutics as well as Entrada by means of unconstrained grants. H.G. has absolutely nothing to disclose in regard to the subject matters dealt with in this manuscript. Before 5 years, he has actually also obtained consultancy gratuity from UCB. M.S. got working as a consultant honoraria coming from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and also Solaxa in the past 5 years, all unrelated to the present manuscript. R.S. possesses nothing to disclose relative to the subjects dealt with in this particular manuscript. She has received speaker and/or working as a consultant honoraria or even funding contributions coming from Abbvie, Bial, STADA and also Everpharma in the past 5 years.